C-MYC Signaling Pathway Assay (CAT#: STEM-MB-0335-WXH)

The C-myc gene is mainly activated through amplification and chromosomal translocation rearrangement, and it has an important relationship with the occurrence, development and evolution of tumors in certain tissues. In different human tumor cell lines, including granulocytic leukemia cell lines, retinoblastoma cell lines, certain neuroblastic cell lines, breast cancer cell lines and certain lung cancer cell lines, C-myc or Amplification of C-myc related sequences. C-myc gene amplification has also been observed in human colon cancer cell lines. C-myc oncogene has been found in osteosarcoma, chondrosarcoma, chordoma, liposarcoma, and rhabdomyosarcoma Amplification was found. When the amplification reached 30 times, HSR and DMS appeared on the chromosome, and the overexpression of C-myc was related to the early tumor recurrence. In tumorigenesis, ras and myc, sis and myc, myc and fos were found Coupling activation, synergistic tumorigenesis and so on.

To study the regulation mechanism of C-MYC signal pathway in disease
To study the effect of each virus on C-MYC signaling pathway
To study the effects of drugs or therapies on C-MYC signaling pathways

• Luminex Multiplex Assay
• Enzyme-linked immunosorbent assay (ELISA)
• Flow cytometry (FACS analysis) technology

Detectable targets: RTK, PI3K, TYK2, STAT1, STAT2, STAT3, STAT5, IRAK4, JNK, MYD88, Rac1, TLR4, CREB, IRF3, MAPK, NAP1, Rel, TLR9, TCR, icam1, Mda-5, NFκB, RIG-1, TRAF3, GAS, IRF9, MEKK1, p38, RIP1, TRAF5, CD3, IRF5, MEK3, p38MAPK, SH2, TRAF6, MHC-II, IRS1, MEK6, p50, SLP76, TRAM, TNFR, ISGF3, MSK2, PI3K, TBK1, Vav, PSGL1, IRS2, MSK1, TLR3, Tak1, TRIF, Fas, ISRE, mTOR, PKR